Patents Examined by Cheng Lu
-
Patent number: 11471519Abstract: The present application provides methods of preparing tumor antigen-specific T cells comprising enriching activated T cells from a first co-culture comprising a first population of antigen-loaded dendritic cells loaded and a population of T cells, and co-culturing the enriched activated T cells with a second population of antigen-loaded dendritic cells. Also provided are methods of treating cancer in an individual using the tumor antigen-specific T cells, pharmaceutical compositions and kits for cell-based cancer immunotherapy.Type: GrantFiled: January 7, 2022Date of Patent: October 18, 2022Assignees: SYZ Cell Therapy Co., HRYZ (Shenzhen) Biotech Co.Inventors: Xiangjun Zhou, Yanyan Han, Xihe Chen, Xiaoling Liang
-
Patent number: 11459394Abstract: The present invention is directed to binding molecules that possess one or more epitope-binding sites specific for an epitope of CD137 and one or more epitope-binding sites specific for an epitope of a tumor antigen (“TA”) (e.g., a “CD137×TA Binding Molecule”). In one embodiment, such CD137×TA Binding Molecules will be bispecific molecules, especially bispecific tetravalent diabodies, that are composed of two, three, four or more than four polypeptide chains and possessing two epitope-binding sites each specific for an epitope of CD137 and two epitope-binding sites each specific for an epitope of a TA. Alternatively, such CD137×TA Binding Molecules will be bispecific molecules, especially bispecific trivalent binding molecules composed of three or more polypeptide chains and possessing one or two epitope-binding sites each specific for an epitope of CD137 and one or two epitope-binding sites each specific for an epitope of a TA.Type: GrantFiled: February 22, 2018Date of Patent: October 4, 2022Assignee: MACROGENICS, INC.Inventors: Liqin Liu, Chia-Ying Kao Lam, Gundo Diedrich, Leslie S. Johnson, Paul A. Moore, Ezio Bonvini
-
Patent number: 11453724Abstract: The present disclosure provides a recombinant fusion protein containing an extracellular Ig-like domain of a signal-regulator protein (SIRP), linked via a linker, to a paratope of an Ig-like anti-HER2 antibody at the N-terminus of a heavy chain or a light chain constituting the paratope. The present disclosure also provides a polynucleotide encoding the recombinant fusion protein, an expression vector containing the polynucleotide, a method for producing the recombinant protein and a method for treating a disease caused by over-expression of CD47 and/or HER2.Type: GrantFiled: August 8, 2019Date of Patent: September 27, 2022Assignee: IMMUNEONCO BIOPHARMACEUTICALS (SHANGHAI) INC.Inventors: Wenzhi Tian, Song Li
-
Patent number: 11446378Abstract: Disclosed herein are compositions and methods for tumor treatment involving administering to a subject having a tumor with an amount effective to limit tumor growth or metastasis of an ephrin B1 inhibitor, or a pharmaceutically acceptable salt thereof; and/or an inhibitor of tumor exosomal release, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: February 23, 2018Date of Patent: September 20, 2022Assignee: Sanford HealthInventor: Paola Vermeer
-
Patent number: 11435354Abstract: There is provided a simple and minimally invasive adenocarcinoma detection method. The adenocarcinoma detection method of the present invention includes a step of detecting in vitro a presence or absence of an abnormal cleavage in a specific protein in a test subject-derived sample. The abnormal cleavage in the specific protein is, for example, a cleavage resulting in one or more breaks in a peptide bond in the specific protein and/or a cleavage resulting in a deletion of one or two more amino acid residues at one or more sites of the specific protein. The adenocarcinoma detection method of the present invention includes a step of detecting a presence or amount of a protein having the abnormal cleavage or a decrease in an amount of a normal protein.Type: GrantFiled: February 16, 2017Date of Patent: September 6, 2022Assignees: UNIVERSITY OF MIYAZAKI, OSAKA UNIVERSITYInventors: Masamitsu Nakazato, Nobuhiro Matsumoto, Yasuji Arimura, Hironobu Tsubouchi, Toshifumi Takao, Nobuaki Okumura, Masafumi Fukuda
-
Patent number: 11434301Abstract: Disclosed herein are methods of treating a subject having a cancer characterized by a modification at biomarker 1q21, which comprises administering to the subject a therapeutically effective amount of an anti-CD46 antibody.Type: GrantFiled: November 10, 2017Date of Patent: September 6, 2022Assignee: The Regents of the University of CaliforniaInventors: Bin Liu, Daniel W. Sherbenou, Blake T. Aftab, Yang Su, Christopher R. Behrens
-
Patent number: 11427648Abstract: The present invention relates to the field of diagnostic and treatment of cancer, particularly melanoma, pancreatic cancer, kidney cancer and colon cancer. In particular, the invention relates to an antibody directed specifically to CD146-positive tumors and its applications, particularly for use as a medicament for the prevention and/or treatment of cancer, for use in a method of diagnostic or prognostic of a cancer, or for use as a radiotracer when labelled with a radioactive element.Type: GrantFiled: October 5, 2018Date of Patent: August 30, 2022Assignees: UNIVERSITE D'AIX-MARSEILLE, ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE)Inventors: Marcel Blot-Chabaud, Benjamin Guillet, Marie Nollet, Jimmy Stalin, Nathalie Bardin, Françoise Dignat-George
-
Patent number: 11414487Abstract: The present invention provides PD-1 monoclonal antibodies, particularly human monoclonal antibodies of PD-1, which specifically bind to PD-1 with high affinity and comprise a heavy chain and a light chain. The present invention further provides nucleic acid sequence encoding the antibodies of the invention, cloning or expression vectors, host cells and methods for expressing or isolating the antibodies. Immunoconjugates, therapeutic compositions comprising the antibodies of the invention are also provided. The invention also provides methods for treating various cancers with anti-PD-1 antibodies.Type: GrantFiled: September 21, 2016Date of Patent: August 16, 2022Assignees: CStone Pharmaceuticals, CStone Pharmaceuticals (Suzhou) Co., Ltd., CStone Pharmaceuticals (Shanghai) Co., Ltd.Inventors: Yong Zheng, Jing Li, Gennady Gololobov, Xinhua Zhang, Baotian Yang, Zhewei Tang, Dong Li, Jianqing Xu, Zhuozhi Wang
-
Patent number: 11400165Abstract: The present disclosure provides methods for site-selectively crosslinking payloads to antibodies and other proteins. This can be accomplished using traceless affinity labels designed to label target proteins with bio-orthogonally reactive entities (ORE) using the compositions and methods described herein.Type: GrantFiled: November 5, 2018Date of Patent: August 2, 2022Assignee: ADVANCED PROTEOME THERAPEUTICS INC.Inventors: Alexander Krantz, Andrzej Wilczynski, Grzegorz Rymarczyk
-
Patent number: 11390685Abstract: Provided is binding protein comprising an antigen binding fragment that specifically binds receptor tyrosine-protein kinase ErbB-2 (ErbB2), polynucleotides encoding the binding protein, vectors comprising the polynucleotides, pharmaceutical composition comprising the binding protein as well as methods of using the binding protein. The binding protein can be used for treating a disease or disorder, in which an ErbB2 activity is detrimental or inhibiting growth of ErbB2 positive cells or tumors synergistically with another ErbB2 antibody such as Trastuzumab. The binding protein can also be used for enhancing internalization of an agent or another ErbB2 antibody, for example, Trastuzumab, into ErbB2 positive cells.Type: GrantFiled: January 4, 2018Date of Patent: July 19, 2022Assignee: BIOSION, INC.Inventor: Mingjiu Chen
-
Patent number: 11377488Abstract: The present invention relates to multifunctional protein molecules comprising decorin and uses thereof. In particular, the present invention relates to multifunctional protein molecules comprising decorin and a targeting polypeptide such as an antibody and methods of their production and uses thereof.Type: GrantFiled: June 28, 2019Date of Patent: July 5, 2022Assignee: CATALENT PHARMA SOLUTIONS, LLCInventor: Gregory T. Bleck
-
Patent number: 11340219Abstract: Methods and compositions are described herein for assaying the presence or absence of pY1235-MET or a fragment thereof.Type: GrantFiled: March 16, 2017Date of Patent: May 24, 2022Assignee: The United States Of America, As Represented by the Secretary, Department Of Health And Human ServicesInventors: Apurva K. Srivastava, Thomas D. Pfister, Tony Navas, Ralph E. Parchment, James E. Doroshow
-
Patent number: 11325976Abstract: Anti-programmed death-ligand 1 (PD-L1) antibodies, methods of using the same, therapeutic compositions thereof, and uses thereof in upregulating cell-mediated immune responses and treating T cell dysfunctional disorders are provided. The use of the anti-PD-L1 antibody as a diagnostic agent in vitro is also provided.Type: GrantFiled: February 16, 2017Date of Patent: May 10, 2022Assignees: XIANGTAN TENGHUA BIOSCIENCEInventor: Ying Zhang
-
Patent number: 11319379Abstract: Disclosed are compositions and methods for targeted treatment of TAG-72-expressing cancers. In particular, affinity maturated single chain variable fragment (scFv) antibodies that bind TAG-72 on cancer cells are disclosed.Type: GrantFiled: August 4, 2017Date of Patent: May 3, 2022Assignee: H. Lee Moffitt Cancer Center and Research Institute, Inc.Inventor: Hatem Soliman
-
Patent number: 11320435Abstract: A method for collecting information about the health status of a subject is proposed involving the quantitative detection, in serum, plasma or blood of the subject, of the concentration of THBS1, the proportion of free PSA (% fPSA), preferably including the concentration of at least one protein selected from the group consisting of CTSD, OLFM4, ICAM1.Type: GrantFiled: July 11, 2017Date of Patent: May 3, 2022Assignee: ProteoMedix AGInventors: Ralph Schiess, Kathrin Endt, Alcibiade Athanasiou, Annalisa Macagno, Thomas Steuber
-
Patent number: 11300570Abstract: The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma. The invention provides methods of treating cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma), methods of determining whether a patient suffering from cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma) is likely to respond to treatment comprising a PD-L1 axis binding antagonist, methods of predicting responsiveness of a patient suffering from cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma) to treatment comprising a PD-L1 axis binding antagonist, and methods of selecting a therapy for a patient suffering from cancer (e.g.Type: GrantFiled: April 1, 2019Date of Patent: April 12, 2022Assignees: Genentech, Inc., Foundation Medicine, Inc.Inventors: David Fabrizio, Garrett M. Frampton, Priti Hegde, Marcin Kowanetz, David Shames, Philip J. Stephens, James Xin Sun, Roman Yelensky, Wei Zou
-
Patent number: 11292842Abstract: The present invention provides methods for treating, reducing the severity, or inhibiting the growth of cancer (e.g., lung cancer). The methods of the present invention comprise administering a therapeutically effective amount of a programmed death 1 (PD-1) antagonist (e.g., an anti-PD-1 antibody), to a subject with lung cancer wherein the cancer tissue expresses PD-L1.Type: GrantFiled: February 20, 2018Date of Patent: April 5, 2022Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Petra Rietschel, Israel Lowy
-
Patent number: 11274155Abstract: Provided are anti-PD-L1 antibodies, variants, mutants, and antigen binding fragments thereof. Also provided are isolated nucleic acid molecules that encode the anti-PD-L1 antibodies, variants, mutants, or antigen binding fragments thereof, and related expression vectors, and host cells. Provided are methods of making anti-PD-L1 antibodies, variants, mutants, and antigen binding fragments thereof. Also provided are related pharmaceutical compositions and methods of their use to treat subjects. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.Type: GrantFiled: April 10, 2019Date of Patent: March 15, 2022Assignee: Shanghai Henlius Biotech Inc.Inventors: Weidong Jiang, Pei-Hua Lin, Chi-Ling Tseng
-
Patent number: 11254752Abstract: The present invention provides methods for treating, reducing the severity, or inhibiting the growth of cancer (e.g., ovarian cancer or pancreatic cancer). The methods of the present invention comprise administering to a subject in need thereof a therapeutically effective amount of an antibody or antigen-binding fragment thereof that specifically binds to programmed death 1 (PD-1) receptor in combination with a therapeutically effective amount of a bispecific antibody that specifically binds Mucin 16 (MUC16) and CD3.Type: GrantFiled: June 20, 2019Date of Patent: February 22, 2022Assignee: Regeneron Pharmaceuticals, Inc.Inventor: Alison Crawford
-
Patent number: 11219676Abstract: The present application provides methods of preparing tumor antigen-specific T cells comprising enriching activated T cells from a first co-culture comprising a first population of antigen-loaded dendritic cells loaded and a population of T cells, and co-culturing the enriched activated T cells with a second population of antigen-loaded dendritic cells. Also provided are methods of treating cancer in an individual using the tumor antigen-specific T cells, pharmaceutical compositions and kits for cell-based cancer immunotherapy.Type: GrantFiled: April 12, 2019Date of Patent: January 11, 2022Assignees: SYZ Cell Therapy Co., HRYZ (Shenzhen) Biotech Co.Inventors: Xiangjun Zhou, Yanyan Han, Xihe Chen, Xiaoling Liang